Dynamic modeling of signal transduction by mTOR complexes in cancer

Area of Science:

• Cellular signaling pathways
• Cancer biology
• Mathematical modeling

Background:

• Dysregulation of cellular signaling pathways, particularly mTOR, is a hallmark of cancer.
• mTOR (mechanistic Target of Rapamycin) integrates signals controlling cell fate, proliferation, and metabolism.
• Rapamycin's differential effects on mTORC1 and mTORC2 complexes are complex and not fully understood.

Purpose of the Study:

• To elucidate the mechanism behind rapamycin's differential inhibition of mTORC1 and mTORC2 in cancer cells.
• To develop a mathematical model based on Le Chatelier's principle to explain rapamycin's action.
• To analyze the dose- and time-dependent dynamics of rapamycin's effects on mTOR signaling.

Main Methods:

• Development of a mathematical model simulating rapamycin's interaction with mTORC1 and mTORC2 components.
• Application of Le Chatelier's principle to model rapamycin's sequestration of free mTOR.
• Analysis of model predictions across various rapamycin concentrations and treatment durations.

Main Results:

• The model demonstrates that rapamycin more strongly inhibits mTORC1 than mTORC2.
• This differential inhibition arises from rapamycin's direct interaction with mTORC1 but not mTORC2.
• The model highlights that mTORC2 can be less sensitive to rapamycin even if inherently less stable.

Conclusions:

• Rapamycin's differential inhibition of mTORC1 and mTORC2 is explained by its direct binding mechanism, consistent with Le Chatelier's principle.
• The mathematical model provides a quantitative framework for understanding rapamycin's complex pharmacodynamics in cancer.
• These findings offer insights into optimizing rapamycin-based cancer therapies by considering differential complex inhibition.